LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - Generic Drug Details

What are the generic drug sources for lutetium lu-177 vipivotide tetraxetan and what is the scope of patent protection?

Lutetium lu-177 vipivotide tetraxetan is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lutetium lu-177 vipivotide tetraxetan has ninety-seven patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

International Patents:	97
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	6
DailyMed Link:	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	Phase 3
Maria Sklodowska-Curie National Research Institute of Oncology	Phase 2
Novartis Pharmaceuticals	Phase 2

See all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN clinical trials

Pharmacology for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Drug Class	Radioligand Therapeutic Agent
Mechanism of Action	Radioligand Activity

US Patents and Regulatory Information for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes			Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes			Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes			Y	Y

International Patents for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Country	Patent Number	Title	Estimated Expiration
Mexico	2021008977	INHIBIDORES MARCADOS DE ANTIGENO PROSTATICO ESPECIFICO DE MEMBRAMA (PSMA), SU USO COMO AGENTES FORMADORES DE IMAGENES Y AGENTES FARMACEUTICOS PARA EL TRATAMIENTO DE CANCER DE PROSTATA. (LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER.)
Hungary	E047200
Chile	2016000883	Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
South Africa	201907607	LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
South Korea	20210013350	전립선 특이적 막 항원（ＰＳＭＡ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제 (LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN PSMA THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER)
China	105636924	Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Israel	245113	מעכבים מסומנים של אנטיגן ממברנה ספציפי לערמונית (psma), השימוש בהם כחומרי הדמיה וכחומרי רוקחות לטיפול בסרטן הערמונית (Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer)